CHMP Recommended Conditional Marketing Authorization In EU For Elrexfio As A Monotherapy For Adults With Relapsed And Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
The Committee for Medicinal Products for Human Use (CHMP) has recommended conditional marketing authorization in the European Union for Elrexfio, a treatment for adults with relapsed and refractory multiple myeloma. The news may impact Pfizer Inc. (PFE), which could be mentioned in the article.
October 13, 2023 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer Inc. may be impacted by the CHMP's recommendation for conditional marketing authorization of Elrexfio in the EU.
The recommendation for conditional marketing authorization of Elrexfio in the EU could potentially lead to increased sales and revenues for Pfizer, if they are indeed involved in the production or distribution of this drug. This could positively impact their stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75